NasdaqGS - Nasdaq Real Time Price USD

Regeneron Pharmaceuticals, Inc. (REGN)

893.99

-7.20

(-0.80%)

At close: April 18 at 4:00 PM EDT

904.00

+10.01

(+1.12%)

Pre-Market: 7:33 AM EDT

Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success

Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.

Zacks 18 hours ago

REGN
-0.80%
NMRA
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks yesterday

PODD

REGN
-0.80%
Why Regeneron (REGN) Could Beat Earnings Estimates Again

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks 2 days ago

REGN
-0.80%
UPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulation

Regeneron Pharmaceuticals said on Monday it seeks to defend against U.S. Department of Justice's complaint that alleged the company misreported the average sales price of its macular degeneration drug Eylea. "Reimbursing credit card service fees to distributors is not a price concession and does not affect EYLEA's price," Regeneron said in a statement, adding that it considered the complaint to be "meritless". The DOJ last week, in a complaint filed in federal court in Boston, alleged the drugmaker failed for years to report how it paid hundreds of millions of dollars to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees.

Reuters 3 days ago

REGN
-0.80%
Regeneron to defend against DOJ complaint on drug-price manipulation

"Reimbursing credit card service fees to distributors is not a price concession and does not affect EYLEA's price," Regeneron said in a statement, adding that it considered the complaint to be "meritless". The DOJ last week, in a complaint filed in federal court in Boston, alleged the drugmaker failed for years to report how it paid hundreds of millions of dollars to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees.

Reuters 3 days ago

REGN
-0.80%
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation

Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and it plans to defend this case in court. The Justice Department last week had accused Regeneron of manipulating Medicare's drug-pricing process by inflating the average sales price for its Eylea drug.

Reuters 3 days ago

REGN
-0.80%
Regeneron commits $500M to new venture capital fund

While corporate venture arms are commonplace among pharmaceutical companies, the new fund announced Monday is Regeneron’s first.

BioPharma Dive 4 days ago

REGN
-0.80%
Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.

Antitrust lawsuits have declined since the pandemic despite a high-profile push by Washington to limit the concentration of power in key industries.

Yahoo Finance 4 days ago

COST

GOOG

META
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.

Zacks 6 days ago

REGN
-0.80%
These Stocks Moved the Most Today: CarMax, Apple, Fastenal, Rivian, Alpine Immune, Nike, Robinhood, Constellation Brands, and More

Earnings at CarMax miss analysts’ estimates, Alpine Immune Sciences is being acquired by Vertex Pharmaceuticals for $4.9 billion in cash, Robinhood stock is downgraded, and Nike receives an upgrade.

Barrons.com 7 days ago

REGN
-0.80%
COST

ALPN
Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands

**Alpine Immune Sciences (ALPN)**: Biotech company **Vertex Pharmaceuticals (VRTX)** agreed to buy Alpine for $4.9 billion, to bolster its kidney-disease portfolio. The target company's shares soared over 36%, extending Wednesday's gains.

The Wall Street Journal 7 days ago

BA

STZ

VRTX
+0.10%
Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?

Regeneron stock toppled Thursday after the DOJ filed a lawsuit saying the drugmaker fraudulently inflated the prices of its drug, Eylea.

Investor's Business Daily 7 days ago

REGN
-0.80%
Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised

The Dow fell after initially rising on the PPI inflation report on the stock market today. Analysts hiked Microsoft and Nvidia price targets.

Investor's Business Daily 7 days ago

MSFT

NVDA

COMP
US sues Regeneron, alleging false price reporting on Eylea

The lawsuit claims the drugmaker didn’t disclose reimbursement to drug distributors for credit card fees, artificially inflating the reported price of the blockbuster eye drug.

BioPharma Dive 8 days ago

REGN
-0.80%
US accuses Regeneron of fraudulent price reporting for eye drug

BOSTON (Reuters) -The U.S. Justice Department on Wednesday accused Regeneron Pharmaceuticals of manipulating Medicare's drug-pricing process by inflating the average sales price for its expensive macular degeneration drug Eylea. The department, in a complaint filed in federal court in Boston, alleged the drugmaker failed for years to report how it paid hundreds of millions of dollars to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees. Those payments were made to ensure that specialty drug distributors would accept credit cards from doctors and retina practices purchasing Eylea while continuing to charge physicians a lower price, according to the lawsuit.

Reuters 8 days ago

REGN
-0.80%
UPDATE 2-US accuses Regeneron of fraudulent price reporting for eye drug

The U.S. Justice Department on Wednesday accused Regeneron Pharmaceuticals of manipulating Medicare's drug-pricing process by inflating the average sales price for its expensive macular degeneration drug Eylea. The department, in a complaint filed in federal court in Boston, alleged the drugmaker failed for years to report how it paid hundreds of millions of dollars to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees. The drug, which the Tarrytown, New York-based company began marketing in 2011, is approved by the U.S. Food and Drug Administration for treating conditions including wet age-related macular degeneration, which impairs vision.

Reuters 8 days ago

REGN
-0.80%
An Intrinsic Calculation For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Suggests It's 47% Undervalued

Key Insights Regeneron Pharmaceuticals' estimated fair value is US$1,774 based on 2 Stage Free Cash Flow to Equity...

Simply Wall St. 8 days ago

REGN
-0.80%
EXEL or REGN: Which Is the Better Value Stock Right Now?

EXEL vs. REGN: Which Stock Is the Better Value Option?

Zacks 9 days ago

EXEL

REGN
-0.80%
11 Best Biotech ETFs To Buy

In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]

Insider Monkey 10 days ago

AMGN
-0.50%
NTRA

NBIX
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) at the American Association for Cancer Research (AACR) An

GlobeNewswire 11 days ago

REGN
-0.80%

Performance Overview

Return	REGN	S&P 500
YTD	+1.79%	+5.06%
1-Year	+9.06%	+20.71%
3-Year	+77.87%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Regeneron Pharmaceuticals, Inc. (REGN)

Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why Regeneron (REGN) Could Beat Earnings Estimates Again

UPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulation

Regeneron to defend against DOJ complaint on drug-price manipulation

Regeneron to defend US Justice Department's complaint on drug-pricing manipulation

Regeneron commits $500M to new venture capital fund

Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.

Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

These Stocks Moved the Most Today: CarMax, Apple, Fastenal, Rivian, Alpine Immune, Nike, Robinhood, Constellation Brands, and More

Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands

Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?

Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised

US sues Regeneron, alleging false price reporting on Eylea

US accuses Regeneron of fraudulent price reporting for eye drug

UPDATE 2-US accuses Regeneron of fraudulent price reporting for eye drug

An Intrinsic Calculation For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Suggests It's 47% Undervalued

EXEL or REGN: Which Is the Better Value Stock Right Now?

11 Best Biotech ETFs To Buy

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

Performance Overview